Investigating the mechanisms underlying this immunosuppressive MHC class I-LILRB1 signaling axis in TAMs will be useful in developing therapies to restore macrophage function46,61, and blocking this pathway may promote antitumor immunity in ESCC. Here, LILRB1 is linked to esophageal squamous cell carcinoma.